61 results about "Steviol" patented technology

To identify the steviol synthetase gene for research and development of metabolic engineering, for example, for increasing a stevioside producing ability. It was successfully found that CYP714A2 derived from Arabidopsis thaliana is surprisingly steviol synthetase. Furthermore, a system in which a large amount of steviol can be biosynthesized was developed by overexpressing this steviol synthetase gene. The steviol synthetase gene is, for example, a polynucleotide encoding a protein which includes the amino acid sequence of SEQ ID NO: 2.

The invention discloses a method for preparing steviol by carrying out catalytic hydrolysis on stevioside by beta-glucosidase, belonging to the field of biosynthesis technology of organic compounds. The method takes the beta-glucosidase derived from aspergillus niger as a catalyst, and can be used for preparing the steviol by carrying out catalytic hydrolysis on the stevioside in single stevioside or stevia rebaudiana extract through temperature programming; the method has the advantages of being high in conversion rate and selectivity, simple in separation and the like; and the enzyme activity loss can be reduced by the temperature programming reaction, so that the utilization rate of enzyme can be improved. The invention provides a new method for preparing the steviol, which is efficient and environment-friendly.

The present invention relates to the use of a substance with the core structure of formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the manufacture of a composition for the treatment of insulin resistance or diseases associated with insulin resistance, preferably in human subject in a daily dosage in a range of from about 5 mg to about 1500 mg. The invention furthermore relates to a method of treating insulin resistance or diseases associated with insulin resistance in a mammal, said method comprises administering to said mamma, preferably a human subject, a substance with the core structure of formula (I), preferably in a daily dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus, insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia, hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability, hypertension, microalbuminuria, or any combinations thereof.

The invention discloses a method for preparing steviol, belonging to the technical field of synthesis of natural compounds. Common Lewis acid is used as a catalyst to directly catalyze the hydrolysis of stevioside to prepare the steviol by a one-step process. The method has the advantages of high selectivity, high conversion rate, simple separation and purification process and the like. The invention provides an efficient, simple and cheap novel method for preparing steviol.

The invention relates to microbacterium barkeri XJ strain and application thereof. The preservation number of microbacterium barkeri XJ is CCTCC NO.M2011182. The strain can be used for preparing steviol, particularly, the method comprises the following steps: preparing stevioside or rubusoside into bacterium culture solution or enzymatic conversion solution; adding a proper quantity of bacterium or enzyme, then conversing stevioside or rubusoside into steviol under the conditions of proper conversion liquid quantity, conversion temperature, pH, time and the like; and separating and purifying the conversion solution to obtain high-purity steviol. The invention also provides the method for effectively preparing steviol.

A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

The present invention relates to a compound with the core structure of formula (I), or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof, for use in the treatment of cognitive impairment in a mammal. The compound is preferably isosteviol or steviol, or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof.

This invention is directed to a process for cleaving glycoside residues from stevioside to produce steviol using a commercially available enzyme mixture containing pectinase, CYTOLASE PCL5®. In preferred methods, the reaction takes place in the presence of a yeast culture. Also described are combinations of Helix pomatia enzymes and CYTOLASE PCL5®.

The invention relates to the use of an oral composition comprising steviol, a steviol precursors or Stevia extract as skin tanning agent. It further relates methods of enhancing the natural skin tan by oral administration of an effective amount of Steviol, a Steviol precursor or Stevia extract.

The invention provides a chemically pure C19-site carboxyl protected steviol derivative. The chemically pure C19-site carboxyl protected steviol derivative is obtained by carrying out acid-catalyzed hydrolysis, silication, epoxidation and reduction on stevia leaf crude extract powder in sequence to obtain a C19-site carboxyl protected steviol derivative and isosteviol of steviol, which have greatpolar difference, and separating two products by adopting a simple and easy-to-operate operation manner; after the steviol derivative is subjected to deprotection, the steviol is obtained; the derivative also can be used for distinguishing active regions of C19 and C13, so that different reaction sites can be conveniently and subsequently subjected to operation of different functional groups.

The invention belongs to the technical field of natural compound biosynthesis and particularly relates to a method for preparing steviol through a two-enzyme method. According to the method for preparing steviol through the two-enzyme method, stevioside is used as a substrate and prepared into a solution with water or a buffer solution, beta-glucosidase-S-bgl4 and Sbgl are added in sequence, a reaction is carried out for 1-12 h, and steviol can be obtained. The method is used for preparing steviol and has the advantages that selectivity, the conversion rate and the yield are high, conditions are mild, environment friendliness is achieved, and operation is easy.

The invention discloses a recombinant escherichia coli engineering bacterium pSE-sbgl-spbgl1 and a method for whole-cell catalytic production of steviol by the recombinant escherichia coli engineeringbacterium pSE-sbgl-spbgl1. The strain co-expresses double beta-glucosidase SPBGL1 and SBGL in a polycistron form, and with a stevia rebaudiana crude extract as a substrate, stevioside and rubusosidein the stevia rebaudiana crude extract are catalyzed to be hydrolyzed to produce steviol by using the whole-cell catalysis method. The engineering bacterium pSE-sbgl-spbgl1 is used for catalyzing stevioside to produce steviol in a whole-cell mode, and the method has the advantages of being high in conversion rate, high in yield, single in product, low in energy consumption, short in consumed time,easy to operate, high in industrialization potential and the like.

The invention discloses application of glucoside in promoting in-vitro proliferation of bone marrow mesenchymal stem cells. The steviol-19-glucoside is a glycoside compound which is widely used and has a natural source. The invention finds that: the steviol-19-glucoside has the effect of promoting hBMSCs proliferation in vitro, and the stem cell characteristics of hBMSCs cannot be obviously reduced. Therefore, the steviol-19-glucoside has the effect of promoting hBMSCs in-vitro proliferation, and has the prospect of being developed into a culture medium for promoting hBMSCs in-vitro proliferation.

The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein.

The invention provides a preparation method of Rebaudioside D, a product and application of the Rebaudioside D. The preparation method comprises the steps that steviol glycosides is taken as a raw material, ethyl acetate and beta-cyclodextrin are taken as glycosyl donors, a conversion reaction takes place under the catalysis of a complex enzyme, and the Rebaudioside D is generated. According to the preparation method of the Rebaudioside D, the product and application of the Rebaudioside D, the cheap and easily obtained ethyl acetate and beta-cyclodextrin are taken as the glycosyl donors to replace high-cost UDP-Glucose to generate the Rebaudioside D under the catalysis of the complex enzyme. The reaction opens a new way for the preparation of the Rebaudioside D, the product yield of the reaction is high, the preparation process is simple, and the reaction is applicable to industrial production and has broad application prospects.

The invention discloses application of isosteviol (ISV) serving as an active ingredient to treatment of sepsis. Compared with the prior art, the ISV has the characteristics of high efficiency and lowtoxicity. The ISV can significantly improve the survival rate of sepsis mice, inhibit the expression of inflammatory factors IL-6, TNF[alpha] and IL-1[beta] in the bodies of the sepsis mice, and improve the damage of the sepsis to the bodies. The effects show that the ISV can be used for treating the sepsis and has medicine development prospects.

The invention discloses a steviol zirconium catalyst for catalyzing furfural hydrogenation to prepare furfuryl alcohol and a preparation method of the steviol zirconium catalyst, and belongs to the technical field of heterogeneous catalysis. Stevia rebaudiana polyphenol and a zirconium source are mixed according to a specific ratio, and the steviol zirconium catalyst is prepared through a solvothermal method. The steviol zirconium catalyst obtained by the invention can have a good effect of catalyzing furfural hydrogenation with a low dosage under a relatively mild condition, is heterogeneous in a reaction system, is easy to separate and reuse, still maintains excellent catalytic performance after being reused for multiple times, and has a very good application prospect.